Smith, Moore & Co’s ARK Genomic Revolution ETF ARKG Stock Holding History

Smith, Moore & Co’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-13,436	Closed	-$1.24M	–	419
2021 Q2	$1.24M	Buy	+13,436	New	+$1.14M	0.19%	102
2020 Q4	–	Sell	-12,788	Closed	-$815K	–	347
2020 Q3	$815K	Buy	+12,788	New	+$749K	0.17%	114

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Smith, Moore & Co's ARKG Position: Q3 2021 in Review

Smith, Moore & Co sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2021, closing a stake of 13,436 shares — an estimated $1.24M sold.

Smith, Moore & Co first reported a position in ARKG in Q3 2020 and held it in 2 quarters. The position peaked at $1.24M in Q2 2021. 469 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.

Smith, Moore & Co reported no remaining ARK Genomic Revolution ETF position as of Q3 2021 after selling out during the quarter.
Smith, Moore & Co sold 13,436 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $1.24M.
Smith, Moore & Co first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 2 quarters.
Smith, Moore & Co's ARK Genomic Revolution ETF position peaked at $1.24M in Q2 2021.
469 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.

Based on Smith, Moore & Co's 13F filing for Q3 2021, filed 12 Nov 2021.